1. A method for manufacturing a suture, the method comprising steps of:
preparing octyl cyanoacetate by reacting cyanoacetic acid and octane alcohol at an equivalence ratio of 1:1 under the existence of a solvent;
reacting the octyl cyanoacetate and paraformaldehyde at an equivalence ratio of 1:1 under the existence of a solvent;
isolating and refining octyl cyanoacrylate after removing the solvent when the reaction is completed;
obtaining poly octyl cyanoacrylate from a byproduct left by refinement of the octyl cyanoacrylate; and
manufacturing a suture by a braid process after fabricating a thread through melt spinning or extrusion molding of the obtained poly octyl cyanoacrylate.
2. The method of claim 1, wherein the solvent is selected from the group consisting of benzene, toluene, and xylan.
3. The method of claim 1, further comprising step of:
coating the suture with a coating composition for a suture.
4. The method of claim 1, wherein the coating composition for a suture is composed of powder type lubricant, at least one surfactant, and polymeric material.
5. A suture manufactured by the method claim 1.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treating retinoid-responsive condition in a subject, comprising:
administering a therapeutically effective amount of a protein selected from: a protein comprising the amino acid of SEQ ID No. 1; a protein comprising the amino acid of SEQ ID No. 2; a protein encoded by the complement of a nucleic acid that hybridizes under highly stringent conditions with the nucleotide sequence of SEQ ID No. 3; a protein encoded by the complement of a nucleic acid that hybridizes under highly stringent conditions with the nucleotide sequence of SEQ HD No. 4; wherein the highly stringent conditions are: hybridization in a solution containing 6\xd7SSC, 5\xd7Denhardt’s solution, 30% formamide, and 100 microgramsml denatured salmon sperm at 37\xb0 C. overnight followed by washing in a solution of 0.1\xd7SSC and 0.1% SDS at 60\xb0 C. for 15 minutes; a protein comprising an amino acid sequence that is at least 95% identical to SEQ ID No. 1; and a protein comprising an amino acid sequence that is at least 95% identical to SEQ ID No. 2, to a subject having a retinoid-responsive condition.
2. The method of claim 1, wherein the retinoid-responsive condition is selected from the group consisting of: acne, rosacea, psoriasis, promyelocytic leukemia and neuroblastoma
3. The method of claim 1, wherein the protein is administered to skin affected by a retinoid-responsive condition selected from the group consisting of: acne, rosacea and psoriasis.
4. The method of claim 1, wherein the protein is administered to skin affected by acne in the subject.
5. A method of treating a retinoid-responsive condition in a subject, comprising:
administering a therapeutically effective amount of a substance selected from the group consisting of: neutrophil gelatinase-associated lipocalin (NGAL), an NGAL analog, an NGAL stimulator and an analog of an NGAL stimulator, to a subject having a retinoid-responsive condition.
6. The method of claim 5, wherein the NGAL analog is an NGAL receptor agonist.
7. The method of claim 5, wherein the NGAL is encoded by a nucleic acid in an expression vector.
8. The method of claim 5, wherein the NGAL stimulator is selected from the group consisting of: a Toll-like receptor 2 ligand, a Toll-like receptor 3 ligand, an activator of NF\u03baB, leukotriene B4, cholesterol oleate and IL-17.
9. The method of claim 5, wherein the activator of NF\u03baB is selected from the group consisting of: IL1-beta and TNF-alpha.
10. The method of claim 8, wherein the Toll-like receptor 2 ligand is N-Palmitoyl-S-2,3-bis(palmitoyloxy)-(2RS)-propyl-R-cysteinyl-S-seryl-S-lysyl-S-lysyl-S-lysyl-S-lysine.
11. The method of claim 8, wherein the Toll-like receptor 3 ligand is polyinosinic:polycytidylic acid.
12. The method of claim 5, wherein the retinoid-responsive condition is selected from the group consisting of: acne, rosacea, psoriasis, promyelocytic leukemia and neuroblastoma.
13. The method of claim 5, wherein the substance is administered to skin affected by a retinoid-responsive condition selected from the group consisting of: acne, rosacea and psoriasis.
14. The method of claim 5, wherein the substance is administered to skin affected by acne in the subject.
15. A method of treating a retinoid-responsive condition in a subject, comprising:
stimulating NGAL expression in a subject having acne.
16. The method of treating a retinoid-responsive condition in a subject of claim 15, wherein NGAL expression is stimulated by administration of an NGAL stimulator which upregulates transcription of a gene encoding NGAL.
17. The method of treating acne in a subject of claim 15, wherein NGAL expression is stimulated by administration of a nucleic acid encoding NGAL to the subject.
18. The method of claim 16, wherein the NGAL stimulator is selected from the group consisting of: a Toll-like receptor 2 ligand, a Toll-like receptor 3 ligand, an activator of NF\u03baB, leukotriene B4, cholesterol oleate and IL-17.
19. The method of claim 18, wherein the activator of NF\u03baB is selected from the group consisting of: IL1-beta and TNF-alpha.
20. The method of claim 18, wherein the Toll-like receptor 2 ligand is N-Palmitoyl-S-2,3-bis(palmitoyloxy)-(2RS)-propyl-R-cysteinyl-S-seryl-S-lysyl-S-lysyl-S-lysyl-S-lysine.
21. The method of claim 18, wherein the Toll-like receptor 3 ligand is polyinosinic:polycytidylic acid.
22. A method of inhibiting Propionibacterium acnes, comprising:
contacting a Propionibacterium acnes bacterium with a substance selected from the group consisting of: NGAL and an NGAL analog.
23. The method of inhibiting Propionibacterium acnes of claim 22, wherein the Propionibacterium acnes bacterium is in contact with a human subject.
24. The method of inhibiting Propionibacterium acnes of claim 23, wherein the human subject has acne.
25. The method of inhibiting Propionibacterium acnes of claim 23, wherein the human subject has rosacea.
26. A composition for treating a retinoid-responsive condition in a subject, comprising a substance selected from the group consisting of: neutrophil gelatinase-associated lipocalin (NGAL), an NGAL analog, an NGAL stimulator, an analog of an NGAL stimulator and a combination of two or more of: neutrophil gelatinase-associated lipocalin (NGAL), an NGAL analog, an NGAL stimulator and an analog of an NGAL stimulator.
27. The composition of claim 26, wherein the NGAL stimulator is selected from the group consisting of: a Toll-like receptor 2 ligand, a Toll-like receptor 3 ligand, an activator of NF\u03baB, N-Palmitoyl-S-2,3-bis(palmitoyloxy)-(2RS)-propyl-R-cysteinyl-S-seryl-S-lysyl-S-lysyl-S-lysyl-S-lysine, polyinosinic-polycytidylic acid, leukotriene B4, cholesterol oleate, IL-17 and a combination of two or more of a Toll-like receptor 2 ligand, a Toll-like receptor 3 ligand, an activator of NF\u03baB, N-Palmitoyl-S-2,3-bis(palmitoyloxy)-(2RS)-propyl-R-cysteinyl-S-seryl-S-lysyl-S-lysyl-S-lysyl-S-lysine, polyinosinic:polycytidylic acid, leukotriene B4, cholesterol oleate and IL-17.
28. The composition of claim 26, wherein the substance is selected from: a protein comprising the amino acid of SEQ ID No. 1; a protein comprising the amino acid of SEQ ID No. 2; a protein encoded by the complement of a nucleic acid that hybridizes under highly stringent conditions with the nucleotide sequence of SEQ ID No. 3; a protein encoded by the complement of a nucleic acid that hybridizes under highly stringent conditions with the nucleotide sequence of SEQ ID No. 4; wherein the highly stringent conditions are: hybridization in a solution containing 6\xd7SSC, 5\xd7Denhardt’s solution, 30% formamide, and 100 microgramsml denatured salmon sperm at 37\xb0 C. overnight followed by washing in a solution of 0.1\xd7SSC and 0.1% SDS at 60\xb0 C. for 15 minutes; a protein comprising an amino acid sequence that is at least 95% identical to SEQ ID No. 1; and a protein comprising an amino acid sequence that is at least 95% identical to SEQ ID No. 2, to a subject having a retinoid-responsive condition